secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kymera Therapeutics, Inc. (KYMR)
CIK:        0001815442
Form:       8-K
Filed at:   2024-04-01T23:59:59+00:00
Accession:  0001193125-24-082641
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Kymera appoints Felix J. Baker as director and Lead Independent Director
------------------------------------------------------------------------

- Felix J. Baker appointed to Board as Class II director effective March 28, 2024; also named Lead Independent Director.
- Dr. Baker is managing member of Baker Bros. Advisors LP, which is affiliated with shareholders holding >5% of stock.
- Baker affiliates purchased 4,950,495 pre-funded warrants at $25.2499 each in January 2024; Dr. Baker deemed beneficial owner.
- Compensation: option to purchase 32,000 shares at closing price on March 28, vesting over 3 years; annual retainer $60,000 as Lead Independent Director.
- Board determined Dr. Baker independent under Nasdaq standards; committee assignments pending.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815442/000119312524082641/0001193125-24-082641-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815442/000119312524082641/d812269d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-082641

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer